A health department spokesperson says the PBAC has not decided to cap the number of cost-effectiveness analysis submissions at 32. Yet it has decided that it can only meet its legal obligations under the Act with a cap of 32 in March. Clearly, there is a cap. The question is the basis on which it is applied.
This circular and semantic argument ends with one conclusion - a submission cap
October 31, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 - - Australian Biotech -
Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics
May 29, 2025 - - Latest News -
TGA approves new therapy for children with growth hormone deficiency
May 29, 2025 - - Latest News -
AbbVie Australia appoints Dr Carly Levetan associate medical director
May 29, 2025 - - Latest News -
For patients, it's about understanding their experience and accessing the touchpoints
May 29, 2025 - - Latest News -
Priceline Pharmacy launches annual event with national menopause project
May 28, 2025 - - Latest News -
Anne Ruston welcomes her reappointment to health and the addition of NDIS
May 28, 2025 - - Latest News